Diblock copolymers and polynucleotide complexes thereof for delivery into cells

Patent metadata

Field	Value
Publication number	US-9862792-B2
Application number	US-201615264392-A
Country	US
Kind code	B2
Filing date	Sep 13, 2016
Priority date	May 13, 2008
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A copolymer comprising a diblock copolymer, the diblock copolymer having the chemical Formula I:

wherein
A 0 , A 1 , A 2 , A 3 , and A 4 are independently selected from the group consisting of —C—C—, —C(O)(C) a C(O)O—, and —O(C) a C(O)—, wherein a is 1-4;
Y 4 is selected from the group consisting of hydrogen, -(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl, —C(O)O(1C-10C)alkyl, —C(O)NR 6 (1C-10C) and aryl, any of which is optionally substituted with one or more fluorine groups;
Y 0 , Y 1 and Y 2 are independently selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C) alkyl-, —OC(O)(1C-10C) alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, and —C(O)NR 6 (2C-10C) alkyl-;
Y 3 is selected from the group consisting of a covalent bond, -(1C-10C)alkyl- and -(6C-10C)aryl-; wherein tetravalent carbon atoms of A 0 -A 4 that are not fully substituted with R 1 -R 5 and Y 0 -Y 4 are completed with an appropriate number of hydrogen atoms;
R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, —CN, alkyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any of which is optionally substituted with one or more fluorine atoms;
Q 0 is a residue selected from the group consisting of residues which are hydrophilic at physiologic pH; conjugatable residues; functionalizable residues; and hydrogen;
Q 1 is a residue which is hydrophilic at normal physiological pH;
Q 2 is a residue which is positively charged at normal physiological pH;
Q 3 is a residue which is negatively charged at normal physiological pH, but undergoes protonation at lower pH;
m is a mole fraction of 0 to less than 1.0;
n is a mole fraction of greater than 0 to 1.0; wherein m +n =1;
p is a mole fraction of 0.1 to 0.9;
q is a mole fraction of 0.1 to 0.9;
r is present up to a mole fraction of 0.8; wherein p+q+r=1;
v is from 1 to 25 kDa;
w is from 1 to 50 kDa; and
R 3 -A 2 -Y 2 -Q 2 , R 4 -A 3 -Y 3 -Q 3 , and R 5 -A 4 -Y 4 are present as a random copolymer block.

2. The copolymer of claim 1 , wherein each of A 0 , A 1 , A 2 , A 3 , and A 4 is —C—C—.

3. The copolymer of claim 1 , wherein m is a mole fraction of 0 to 0.49.

4. The copolymer of claim 2 , wherein m is a mole fraction of 0 to 0.49.

5. The copolymer of claim 1 , wherein p is a mole fraction of 0.2 to 0.5.

6. The copolymer of claim 2 , wherein p is a mole fraction of 0.2 to 0.5.

7. The copolymer of claim 1 , wherein p and q are within 0.3 of each other.

8. The copolymer of claim 2 , wherein p and q are within 0.3 of each other.

9. The copolymer of claim 1 , wherein the ratio of w to v is from 5:1 to 1:1.

10. The copolymer of claim 2 , wherein the ratio of w to v is from 5:1 to 1:1.

11. The copolymer of claim 1 , wherein Q 0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q 1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q 2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q 3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

12. The copolymer of claim 2 , wherein Q 0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q 1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q 2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q 3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

13. The copolymer of claim 1 , wherein the copolymer comprises a targeting moiety.

14. The copolymer of claim 2 , wherein the copolymer comprises a targeting moiety.

15. The copolymer of claim 2 , wherein R 3 -A 2 -Y 2 -Q 2 is a residue of a C1-6 dialkylamino(C1-6)alkylmethacrylate, C1-6 alkylamino(C1-6) alkylmethacrylate, amino(C1-6)alkylacrylate, C1-6 dialkylamino(C1-6)alkylethacrylate, C1-6alkylamino(C1-6)alkylethacrylate, amino(C1-6)alkylethacrylate, C1-6dialkylamino(C1-6)alkylacrylate, C1-6 alkylamino(C1-6)alkylacrylate, or amino(C1-6) alkylacrylate.

16. The copolymer of claim 2 , wherein R 4 -A 3 -Y 3 -Q 3 is a residue of a C1-6 alkylacrylic acid.

17. The copolymer of claim 2 , wherein R 5 -A 4- Y 4 is a residue of a C1-6 alkylacrylate, C1-C6 alkylmethacrylate, or C1-C6 alkylethacrylate.

18. A composition comprising:
the copolymer of claim 2 ; and
a therapeutic agent.

19. The composition of claim 18 , wherein the therapeutic agent is a polynucleotide.

20. The composition of claim 19 , wherein the polynucleotide is an RNA.

Assignees

• Univ Washington
• Phaserx Inc

Inventors

• Stayton Patrick S
• Hoffman Allan S
• Convertine Anthony J
• Benoit Danielle
• Duvall Craig L
• Johnson Paul H
• Gall Anna S

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title